Cargando…
Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products
Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult to achieve in most patients. Progression of simple...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834322/ https://www.ncbi.nlm.nih.gov/pubmed/31614491 http://dx.doi.org/10.3390/ijms20205037 |
_version_ | 1783466468937039872 |
---|---|
author | Fernando, Dinali H. Forbes, Josephine M. Angus, Peter W. Herath, Chandana B. |
author_facet | Fernando, Dinali H. Forbes, Josephine M. Angus, Peter W. Herath, Chandana B. |
author_sort | Fernando, Dinali H. |
collection | PubMed |
description | Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult to achieve in most patients. Progression of simple fatty liver or steatosis to its severe form non-alcoholic steatohepatitis (NASH) and liver fibrosis has been explained by a ‘two-hit hypothesis’. Whilst simple steatosis is considered the first hit, its transformation to NASH may be driven by a second hit. Of several factors that constitute the second hit, advanced glycation end products (AGEs), which are formed when reducing-sugars react with proteins or lipids, have been implicated as major candidates that drive steatosis to NASH via the receptor for AGEs (RAGE). Both endogenous and processed food-derived (exogenous) AGEs can activate RAGE, mainly present on Kupffer cells and hepatic stellate cells, thus propagating NAFLD progression. This review focuses on the pathophysiology of NAFLD with special emphasis on the role of food-derived AGEs in NAFLD progression to NASH and liver fibrosis. Moreover, the effect of dietary manipulation to reduce AGE content in food or the therapies targeting AGE/RAGE pathway on disease progression is also discussed. |
format | Online Article Text |
id | pubmed-6834322 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68343222019-11-25 Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products Fernando, Dinali H. Forbes, Josephine M. Angus, Peter W. Herath, Chandana B. Int J Mol Sci Review Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult to achieve in most patients. Progression of simple fatty liver or steatosis to its severe form non-alcoholic steatohepatitis (NASH) and liver fibrosis has been explained by a ‘two-hit hypothesis’. Whilst simple steatosis is considered the first hit, its transformation to NASH may be driven by a second hit. Of several factors that constitute the second hit, advanced glycation end products (AGEs), which are formed when reducing-sugars react with proteins or lipids, have been implicated as major candidates that drive steatosis to NASH via the receptor for AGEs (RAGE). Both endogenous and processed food-derived (exogenous) AGEs can activate RAGE, mainly present on Kupffer cells and hepatic stellate cells, thus propagating NAFLD progression. This review focuses on the pathophysiology of NAFLD with special emphasis on the role of food-derived AGEs in NAFLD progression to NASH and liver fibrosis. Moreover, the effect of dietary manipulation to reduce AGE content in food or the therapies targeting AGE/RAGE pathway on disease progression is also discussed. MDPI 2019-10-11 /pmc/articles/PMC6834322/ /pubmed/31614491 http://dx.doi.org/10.3390/ijms20205037 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Fernando, Dinali H. Forbes, Josephine M. Angus, Peter W. Herath, Chandana B. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products |
title | Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products |
title_full | Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products |
title_fullStr | Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products |
title_full_unstemmed | Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products |
title_short | Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products |
title_sort | development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834322/ https://www.ncbi.nlm.nih.gov/pubmed/31614491 http://dx.doi.org/10.3390/ijms20205037 |
work_keys_str_mv | AT fernandodinalih developmentandprogressionofnonalcoholicfattyliverdiseasetheroleofadvancedglycationendproducts AT forbesjosephinem developmentandprogressionofnonalcoholicfattyliverdiseasetheroleofadvancedglycationendproducts AT anguspeterw developmentandprogressionofnonalcoholicfattyliverdiseasetheroleofadvancedglycationendproducts AT herathchandanab developmentandprogressionofnonalcoholicfattyliverdiseasetheroleofadvancedglycationendproducts |